KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2026)

CRISPR Therapeutics AG's Return on Capital Employed history spans 11 years, with the latest figure at 27.4% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed fell 464.0% to 27.4% in Q1 2026 year-over-year; TTM through Mar 2026 was 27.4%, a 464.0% decrease, with the full-year FY2025 number at 31.58%, down 986.0% from a year prior.
  • Return on Capital Employed hit 27.4% in Q1 2026 for CRISPR Therapeutics AG, up from 31.55% in the prior quarter.
  • Over the last five years, Return on Capital Employed for CRSP hit a ceiling of 12.17% in Q1 2022 and a floor of 31.55% in Q4 2025.
  • Historically, Return on Capital Employed has averaged 21.2% across 5 years, with a median of 22.76% in 2025.
  • The widest YoY moves for Return on Capital Employed: up 3401bps in 2022, down -4548bps in 2022.
  • Tracing CRSP's Return on Capital Employed over 5 years: stood at 30.92% in 2022, then surged by 65bps to 10.86% in 2023, then crashed by -99bps to 21.59% in 2024, then plummeted by -46bps to 31.55% in 2025, then rose by 13bps to 27.4% in 2026.
  • Business Quant data shows Return on Capital Employed for CRSP at 27.4% in Q1 2026, 31.55% in Q4 2025, and 28.46% in Q3 2025.